Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Price Drop

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on May 02, 2022 1:01pm

114 Views

Post# 34648032

RE:Price Drop

What millions? The company has had a trash valuation since the flop of the COVID-19 results. If anything, the company remains overvalued. It has less than 1M USD on hand and no uplist timeline. You'll be lucky if they simply don't go bankrupt at this point with clueless management at the helm.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments